On August 20, EVEREST MED surged 47.06% in regular trading, trading at HKD 35.04/share, with turnover of HKD 1.001 billion. The stock opened approximately 15% higher before accelerating gains through the session on dual catalysts.

On the news front, Moderna and Merck announced on August 19 that their co-developed mRNA personalized cancer vaccine intismeran autogene achieved preliminary positive results in its first Phase III clinical trial for melanoma. Moderna's stock soared nearly 177% overnight, triggering a broad revaluation of the mRNA sector. Concurrently, EVEREST MED released interim results showing H1 revenue of RMB 1.148 billion, up 157.29% year-over-year, with gross profit surging 166.98%. The net loss narrowed dramatically by 97.62% to just RMB 5.944 million, approaching breakeven. Gross margin improved to 69.6%. Revenue growth was primarily driven by strong sales of Nefecon and service income from a commercialization agreement with Haisen Bio.

Within the Biotechnology sector, CANSINOBIO rose 45.67%, REMEGEN gained 7.5%, AKESO climbed 7.84%, INNOVENT BIO added 5.45%, and BEONE MEDICINES advanced 5.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)